OA10998A - Use of benzopyranols to treat neurological disorders - Google Patents
Use of benzopyranols to treat neurological disorders Download PDFInfo
- Publication number
- OA10998A OA10998A OA9900060A OA9900060A OA10998A OA 10998 A OA10998 A OA 10998A OA 9900060 A OA9900060 A OA 9900060A OA 9900060 A OA9900060 A OA 9900060A OA 10998 A OA10998 A OA 10998A
- Authority
- OA
- OAPI
- Prior art keywords
- pain
- treatment
- acetyl
- dimethyl
- compound
- Prior art date
Links
- SERVTOXIOYSDQO-UHFFFAOYSA-N 2h-chromen-2-ol Chemical class C1=CC=C2C=CC(O)OC2=C1 SERVTOXIOYSDQO-UHFFFAOYSA-N 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 208000002193 Pain Diseases 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000004296 neuralgia Diseases 0.000 claims abstract description 9
- 206010044652 trigeminal neuralgia Diseases 0.000 claims abstract description 9
- 206010003591 Ataxia Diseases 0.000 claims abstract description 7
- 206010058019 Cancer Pain Diseases 0.000 claims abstract description 7
- 206010008748 Chorea Diseases 0.000 claims abstract description 7
- 208000002740 Muscle Rigidity Diseases 0.000 claims abstract description 7
- 208000008238 Muscle Spasticity Diseases 0.000 claims abstract description 7
- 208000009205 Tinnitus Diseases 0.000 claims abstract description 7
- 208000012601 choreatic disease Diseases 0.000 claims abstract description 7
- 230000001537 neural effect Effects 0.000 claims abstract description 7
- 201000000980 schizophrenia Diseases 0.000 claims abstract description 7
- 208000019116 sleep disease Diseases 0.000 claims abstract description 7
- 208000018198 spasticity Diseases 0.000 claims abstract description 7
- 231100000886 tinnitus Toxicity 0.000 claims abstract description 7
- 208000017164 Chronobiology disease Diseases 0.000 claims abstract description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 6
- 206010043220 Temporomandibular joint syndrome Diseases 0.000 claims abstract description 6
- 208000000323 Tourette Syndrome Diseases 0.000 claims abstract description 6
- 208000030886 Traumatic Brain injury Diseases 0.000 claims abstract description 6
- 206010022437 insomnia Diseases 0.000 claims abstract description 6
- 201000003631 narcolepsy Diseases 0.000 claims abstract description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 6
- 238000011321 prophylaxis Methods 0.000 claims abstract description 6
- 230000009529 traumatic brain injury Effects 0.000 claims abstract description 6
- 208000030507 AIDS Diseases 0.000 claims abstract description 5
- 208000026072 Motor neurone disease Diseases 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 17
- 201000001119 neuropathy Diseases 0.000 claims description 10
- 230000007823 neuropathy Effects 0.000 claims description 10
- 208000016620 Tourette disease Diseases 0.000 claims description 5
- 230000000926 neurological effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000001562 benzopyrans Chemical class 0.000 abstract description 2
- 241001480592 Chlorophyllum molybdites Species 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000007971 neurological deficit Effects 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 description 36
- 229910052739 hydrogen Inorganic materials 0.000 description 15
- 239000001257 hydrogen Substances 0.000 description 15
- -1 Cj.g alkylsulfïnyl Chemical group 0.000 description 14
- 238000000034 method Methods 0.000 description 11
- 150000002431 hydrogen Chemical group 0.000 description 9
- 229940125782 compound 2 Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 7
- 229940125904 compound 1 Drugs 0.000 description 7
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 125000001589 carboacyl group Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002118 epoxides Chemical class 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 2
- 229960003602 guanethidine Drugs 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000020341 sensory perception of pain Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- OJYGBLRPYBAHRT-OPKHMCHVSA-N Chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H](C(O)CO)OC21 OJYGBLRPYBAHRT-OPKHMCHVSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910004679 ONO2 Inorganic materials 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000005138 alkoxysulfonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000010210 aluminium Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 1
- 125000005204 heteroarylcarbonyloxy group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 description 1
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 208000007656 osteochondritis dissecans Diseases 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 235000008790 seltzer Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 210000000427 trigeminal ganglion Anatomy 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9619492.3A GB9619492D0 (en) | 1996-09-18 | 1996-09-18 | Novel treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA10998A true OA10998A (en) | 2003-03-04 |
Family
ID=10800127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA9900060A OA10998A (en) | 1996-09-18 | 1999-03-18 | Use of benzopyranols to treat neurological disorders |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP0939630B1 (fr) |
| JP (1) | JP2001500520A (fr) |
| KR (1) | KR20000036184A (fr) |
| CN (1) | CN1230885A (fr) |
| AP (1) | AP9901473A0 (fr) |
| AR (1) | AR008838A1 (fr) |
| AT (1) | ATE270102T1 (fr) |
| AU (1) | AU730465B2 (fr) |
| BG (1) | BG103252A (fr) |
| BR (1) | BR9712030A (fr) |
| CA (1) | CA2266681A1 (fr) |
| DE (1) | DE69729735T2 (fr) |
| DZ (1) | DZ2311A1 (fr) |
| EA (1) | EA199900306A1 (fr) |
| ES (1) | ES2223075T3 (fr) |
| GB (1) | GB9619492D0 (fr) |
| HU (1) | HUP9904638A3 (fr) |
| ID (2) | ID23175A (fr) |
| IL (1) | IL128786A0 (fr) |
| MA (1) | MA24321A1 (fr) |
| NO (1) | NO991292D0 (fr) |
| NZ (1) | NZ334271A (fr) |
| OA (1) | OA10998A (fr) |
| PE (1) | PE109898A1 (fr) |
| PL (1) | PL332313A1 (fr) |
| SK (1) | SK35199A3 (fr) |
| TR (1) | TR199900527T2 (fr) |
| UY (1) | UY24717A1 (fr) |
| WO (1) | WO1998011890A1 (fr) |
| ZA (1) | ZA978359B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7119214B2 (en) * | 2004-04-13 | 2006-10-10 | Cephalon France | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives |
| CA2726878A1 (fr) * | 2008-06-05 | 2009-12-10 | Minster Research Limited | Nouveaux traitements |
| WO2009147441A2 (fr) * | 2008-06-05 | 2009-12-10 | Minster Research Limited | Nouveaux traitements |
| CN102725290B (zh) | 2009-07-27 | 2016-03-09 | 吉利德科学股份有限公司 | 作为离子通道调节剂的稠合杂环化合物 |
| RU2012124837A (ru) * | 2009-12-03 | 2014-01-10 | Проксимэджен ЛТД | Лечение аллодинии и гипералгезии |
| EP2506847A1 (fr) * | 2009-12-03 | 2012-10-10 | Proximagen Limited | Traitement de maladies infectieuses |
| NZ604478A (en) | 2010-07-02 | 2014-12-24 | Gilead Sciences Inc | Fused heterocyclic compounds as ion channel modulators |
| BR112013028886A2 (pt) | 2011-05-10 | 2016-08-09 | Gilead Sciences Inc | compostos heterocíclicos fundidos como moduladores dde canal de sódio |
| TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (fr) | 2011-07-01 | 2018-04-28 | ||
| CN106397317B (zh) * | 2016-09-26 | 2019-03-22 | 天津师范大学 | 1,2,3,4-四氢喹啉化合物及其合成方法与应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9112721D0 (en) * | 1991-06-13 | 1991-07-31 | Smithkline Beecham Plc | Novel treatment |
| US5510375A (en) * | 1993-11-19 | 1996-04-23 | Warner-Lambert Company | Coumarin derivatives as protease inhibitors and antiviral agents |
| SI0764157T1 (en) * | 1994-06-10 | 2002-06-30 | Smithkline Beecham Plc | Benzopyrans and their use as therapeutic agents |
| GB9411635D0 (en) * | 1994-06-10 | 1994-08-03 | Smithkline Beecham Plc | Novel treatment |
-
1996
- 1996-09-18 GB GBGB9619492.3A patent/GB9619492D0/en active Pending
-
1997
- 1997-09-15 EA EA199900306A patent/EA199900306A1/ru unknown
- 1997-09-15 DE DE69729735T patent/DE69729735T2/de not_active Expired - Fee Related
- 1997-09-15 HU HU9904638A patent/HUP9904638A3/hu unknown
- 1997-09-15 AP APAP/P/1999/001473A patent/AP9901473A0/en unknown
- 1997-09-15 PL PL97332313A patent/PL332313A1/xx unknown
- 1997-09-15 AT AT97909300T patent/ATE270102T1/de not_active IP Right Cessation
- 1997-09-15 CA CA002266681A patent/CA2266681A1/fr not_active Abandoned
- 1997-09-15 NZ NZ334271A patent/NZ334271A/en unknown
- 1997-09-15 EP EP97909300A patent/EP0939630B1/fr not_active Expired - Lifetime
- 1997-09-15 CN CN97197979A patent/CN1230885A/zh active Pending
- 1997-09-15 BR BR9712030A patent/BR9712030A/pt not_active IP Right Cessation
- 1997-09-15 IL IL12878697A patent/IL128786A0/xx unknown
- 1997-09-15 SK SK351-99A patent/SK35199A3/sk unknown
- 1997-09-15 ID IDW990097A patent/ID23175A/id unknown
- 1997-09-15 JP JP10514309A patent/JP2001500520A/ja not_active Ceased
- 1997-09-15 KR KR1019997002238A patent/KR20000036184A/ko not_active Withdrawn
- 1997-09-15 AU AU47047/97A patent/AU730465B2/en not_active Ceased
- 1997-09-15 TR TR1999/00527T patent/TR199900527T2/xx unknown
- 1997-09-15 ES ES97909300T patent/ES2223075T3/es not_active Expired - Lifetime
- 1997-09-15 WO PCT/EP1997/005168 patent/WO1998011890A1/fr not_active Ceased
- 1997-09-16 MA MA24799A patent/MA24321A1/fr unknown
- 1997-09-16 AR ARP970104238A patent/AR008838A1/es not_active Application Discontinuation
- 1997-09-16 UY UY24717A patent/UY24717A1/es not_active Application Discontinuation
- 1997-09-16 ID IDP973201A patent/ID19542A/id unknown
- 1997-09-17 ZA ZA978359A patent/ZA978359B/xx unknown
- 1997-09-17 DZ DZ970161A patent/DZ2311A1/fr active
- 1997-09-18 PE PE1997000831A patent/PE109898A1/es not_active Application Discontinuation
-
1999
- 1999-03-15 BG BG103252A patent/BG103252A/xx unknown
- 1999-03-17 NO NO991292A patent/NO991292D0/no not_active Application Discontinuation
- 1999-03-18 OA OA9900060A patent/OA10998A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ334271A (en) | 2001-03-30 |
| HUP9904638A2 (hu) | 2001-05-28 |
| PL332313A1 (en) | 1999-08-30 |
| UY24717A1 (es) | 2001-08-27 |
| NO991292L (no) | 1999-03-17 |
| CN1230885A (zh) | 1999-10-06 |
| MA24321A1 (fr) | 1998-04-01 |
| BR9712030A (pt) | 1999-08-24 |
| ATE270102T1 (de) | 2004-07-15 |
| DZ2311A1 (fr) | 2002-12-28 |
| ES2223075T3 (es) | 2005-02-16 |
| EP0939630A1 (fr) | 1999-09-08 |
| JP2001500520A (ja) | 2001-01-16 |
| ID19542A (id) | 1998-07-23 |
| GB9619492D0 (en) | 1996-10-30 |
| DE69729735T2 (de) | 2005-07-14 |
| EA199900306A1 (ru) | 1999-08-26 |
| HUP9904638A3 (en) | 2001-08-28 |
| ID23175A (id) | 2000-03-23 |
| WO1998011890A1 (fr) | 1998-03-26 |
| PE109898A1 (es) | 1999-03-21 |
| SK35199A3 (en) | 2000-07-11 |
| AP9901473A0 (en) | 1999-03-31 |
| DE69729735D1 (de) | 2004-08-05 |
| IL128786A0 (en) | 2000-01-31 |
| KR20000036184A (ko) | 2000-06-26 |
| NO991292D0 (no) | 1999-03-17 |
| ZA978359B (en) | 1999-03-17 |
| AU4704797A (en) | 1998-04-14 |
| AR008838A1 (es) | 2000-02-23 |
| AU730465B2 (en) | 2001-03-08 |
| BG103252A (en) | 1999-09-30 |
| CA2266681A1 (fr) | 1998-03-26 |
| TR199900527T2 (xx) | 1999-06-21 |
| EP0939630B1 (fr) | 2004-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK169593B1 (da) | Farmaceutiske præparater med forbedret stabilitet samt fremgangsmåde til stabilisering af et ACE-inhibitor lægemiddel | |
| EP1343495B1 (fr) | Methodes de traitement des troubles anxieux | |
| OA10998A (en) | Use of benzopyranols to treat neurological disorders | |
| WO2000012073A1 (fr) | Utilisation d'antagonistes du 5-ht¿6? | |
| CN1119147C (zh) | 用于炎性肠疾病的k阿片激动剂 | |
| CA2726878A1 (fr) | Nouveaux traitements | |
| AU607728B2 (en) | Hypertension treatment using k+ channel activator and ace inhibitor agents | |
| CA2335846A1 (fr) | Derives de benzopyrane substitue et leur utilisation comme agents anti-convulsifs | |
| US6492415B2 (en) | Use of benzopyranols to treat neurological disorders | |
| CA1327163C (fr) | Derives de la piperazine a effet anxyolitique | |
| TW448046B (en) | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity | |
| EP1448181B1 (fr) | Composition pharmaceutique contenant une combinaison de metformine et d'un acide 4-oxobutanoique et son utilisation pour traiter le diabete | |
| KR0177894B1 (ko) | 항우울제 | |
| US5886021A (en) | Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for vasodilatory treatment or prophylaxis | |
| JPH0525167A (ja) | 緑内障の治療に有用な置換ベンゼン誘導体 | |
| KR20010021796A (ko) | 선택성 세로토닌 재흡수 억제제 (ｓｓｒｉ)를 사용하는심장 질환의 치료 및 예방법 | |
| CZ92999A3 (cs) | Farmaceutický prostředek pro léčbu a/nebo profylaxi neurologických poruch a použití sloučenin obsahujících fosfor k výrobě léčiva | |
| WO1987003807A1 (fr) | Derives d'oxazole et leur utilisation en tant qu'agents anti-hyperglycemiques | |
| CN110407789B (zh) | 一种防治骨质疏松的药物及其制备方法 | |
| JPS63165317A (ja) | 製薬生成物 | |
| HUT72589A (en) | Benzopyron analogues for the treatment of anxiety, mania, depression or withdrawal symptoms | |
| MXPA00010343A (en) | Treatment of generalized anxiety disorder with paroxetine | |
| CA2328896A1 (fr) | Traitement de trouble anxieux generalise avec de la paroxetine | |
| WO2003047574A1 (fr) | Composition pharmaceutique renfermant un derive de type 5-phenoxyalkyl-2,4-thiazolidinedione et un acide 4-oxobutanoique |